{
  "docId": "019de516-01ce-701d-bd9b-acac15fa9fab",
  "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88",
  "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides",
  "authorId": "oculis",
  "authorName": "Oculis",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 39,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "other",
  "function": "plan_implementation",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/29",
  "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab",
  "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json",
  "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.85,
        "x": 0.09,
        "y": 0.58
      },
      "kind": "diagram",
      "text": "Screening -> 2 week run in, all subjects -> (6+2) weeks -> OCS-02 3x/day -> Follow-up\nArtificial tears TID -> Patients who respond to artificial tears will not be randomized -> Vehicle 3x/day -> Follow-up",
      "attrs": {},
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6b1665f-0b88-450f-9e9a-6f2fe917a5ac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.23,
        "w": 0.26,
        "x": 0.05,
        "y": 0.26
      },
      "kind": "list",
      "text": "Phase 2b Study Design:\nRandomized, masked, vehicle-controlled study\nMulti-center, 10-week, approx. 120 subjects\nStratification based on genotype (CC SNP) 30 Patients",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d877734-d020-4285-8cc9-89783b766677",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.26,
        "x": 0.34,
        "y": 0.26
      },
      "kind": "list",
      "text": "Objectives:\nThe objective of this study is to evaluate the safety and efficacy of OCS-02 for the treatment of signs and symptoms of DED",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a3031057-3412-4f8e-b3fd-8a1f33c787c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.19,
        "w": 0.33,
        "x": 0.63,
        "y": 0.26
      },
      "kind": "list",
      "text": "Key Enrollment Criteria:\nSubjects with history of DED for 6 months\nSchirmer's test at baseline < 10 mm\nCorneal fluorescein stain ≥ 2 in at least 1 region (inferior, superior)",
      "attrs": {},
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e6a88f35-a94a-41d7-897f-ab00f0f2ba17",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.75,
        "x": 0.026,
        "y": 0.09
      },
      "kind": "paragraph",
      "text": "A multi-center, randomized, double-masked, vehicle-controlled study evaluating the safety and efficacy of OCS-02 for the treatment of signs and symptoms of DED",
      "attrs": {},
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5a0b03e-b9b0-4f43-8480-181916350544",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.02,
        "x": 0.95,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "29",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a91ec962-b59f-4f1a-92c5-db78cc9e9dac",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.66,
        "x": 0.026,
        "y": 0.05
      },
      "kind": "title",
      "text": "OCS-02 | Phase 2b Study in Dry Eye Disease",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "43e14735-77ce-49b3-a220-6f101e53e6e9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 39,
      "from": 25,
      "beatId": "6cce666b-f795-4a3e-a589-afe2a7266ece",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Impact & Next Steps",
      "beatSlug": "consultants-gambit-impact-next-steps",
      "evidence": "Slides 25-39 discuss OCS-02, OCS-05, and the track record of efficient capital deployment.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}